Contents

Preface xiii

Acknowledgements xiv

Section 1: Pathology

A survey of some problems related to the structure of the normal pituitary and of pituitary adenomas
J Racadot 3

Immunocyto-chemistry, what does it add to clinical management?
J Trouillas, C Girod, G Sassolas and B Claustrat 11

Correlations between immunocytochemical and clinical data in 675 cases of pituitary adenomas
M Kujas, J Pleau-Varet, F Peillon and P Derome 21

GH and PRL: Hormone studies and immunocytochemical correlates
M Bassetti, A Spada, A Arosio, M Brina and G Giannatasio 23

Occurrence and pattern of cytokeratins in human pituitary adenomas
PhU Heitz, M Oberholzer, HR Zenklusen, M Kasper, JC Reubi, F Gudat, AM Landolt and C Stähli 27

Morphological and immunocytochemical study of 4 intrasellar gangliocytomas
JY Li, O Racadot, M Kujas, M Kouadri, F Peillon and J Racadot 39

Intratumoral cyst formation in pituitary adenoma
Z Ram, G Findler, M Hadani, I Schacked and A Sahar 41

Section 2: Tumor biology

DNA studies for prediction of prognosis of pituitary adenomas
M Anniko and J Wersäll 45

Proliferation of human pituitary adenomas: Facts and speculations
AM Landolt, T Shibata, P Kleihues and E Tuncdogan 53

Antitumor effects of bromocriptine on prolactinomas and GH-secreting adenomas; morphometric analysis
Y Saitoh, N Arita, S Mori, T Hayakawa, H Mogami, Y Oku and H Mori 63

Section 3: Endocrinology, Physiology

Receptor studies in human pituitary adenomas. Do they contribute to a better understanding of their pathogenesis?
F Peillon, D Bression, M Le Dafniet, AM Brandi, JY Li, P Pagesy, P Birman, J Blumberg-Tick, M Michard, M Kujas and J Racadot 67

Central control mechanisms: Their role in the formation of pituitary adenomas
G Faglia, A Spada, B Ambrosi, P Beck-Peccoz, M Arosio, M Bassetti and L Vallar 77

Ectopic production of pituitary hormones and releasing hormones
K von Werder, J Schopohl, G Wolfram, J Mojto, GK Stalla, M Losa and OA Müller 87

Pituitary transplants into third ventricle restore hormone levels after hypophysectomy in adult rats
M Maxwell, PMcL Black, P Riskind, J MacGillivray and C Allegra 97

Electrical activity and cytosolic calcium studied in single cells of human prolactinoma
P Mollard, P Vacher, B Duffy, BP Winiger, GR Zahnd, A Vecsey and W Schlegel 99

Section 4: Diagnostic Radiology

Radiologic anatomy of the sellar region
JF Bonneville, F Cattin and JL Dietemann 105

Age-related changes in the shape of the normal pituitary gland
S Tanabe, J Niwa, M Daibo, T Uede and K Hashi 113

Magnetic resonance imaging (MRI) in the praeoperative diagnosis of pituitary adenomas: comparison with CT
R Fahlbusch, R Nistor, M Buchfelder and W Huk 117

Assessment of pituitary adenomas with MR imaging
N Roosen, E Keck, E Lins, W Stork, D Gahlen and WJ Bock 127

Efficacy of MRI in patients with pituitary adenomas
U Fink, WM Bauer, N Hartmann, R Oeckler, K Bise, K von Werder and D Engelhardt 131

Correlation between CT-scan, MRI and intraoperative findings in pituitary adenomas
Y Gandon, G Brassier, G Edan, B Casin-Nicol, L Campion, J Fairvre and M Carsin 135

Magnetic resonance (MRI) in the pre- and postoperative evaluation of patients with sellar and suprasellar lesions
IS Ciric and M Mikhael 139

Gadolinium-DTPA-enhanced, high resolution MRI-examination of microadenomas
Wichmann W, Haller D, Schubiger O, Valavanis A 141

Radiologic anatomy of the cavernous sinus and its venous drainage
A Valavanis 143

The veins of the cavernous sinus: Usefulness of their demonstration for the diagnosis of invasive pituitary adenomas
JF Bonneville, F Cattin, M Bouchareb, P Potelon, D Boulard and A Racle 151

The use of positron emission tomography (PET) with ^{11}C-labelled L- and D-methionin in diagnosis and follow-up of pituitary adenomas treated with bromocriptine
PO Lundberg, C Muhr, M Bergström, K Bergström, H Lundquist and B Långström 155

Positron emission tomography for the *in vivo* characterization and follow up of treatment in pituitary adenomas
C Muhr, M Bergström, PO Lundberg, K Bergström and B Långström 163

Section 5: Acromegaly

Neural regulation of growth hormone secretion
EE Müller, SG Cella, V Locatelli, V De Gennaro and D Cocchi 173

Stimulation and suppression of endogenous growth hormone in patients with acromegaly
R Illig and T Torresani 183

Influence of theophylline on GHRH-induced GH secretion in vitro
Y Spiess, J Alba-Roth, L Bock, M Losa and K von Werder 189

Incidence and distribution of somatostatin receptors in pituitary, endocrine and brain tumors: Clinical implications
JC Reubi 193

Pituitary adenoma with acromegaly and low plasma GH: undetectable GH mRNA levels
P Pagesy, J Martial, O Delalande, F Rentier-Delrue, P Derome, F Frankenne, M Kujas, P Le Gentil, Y le Bouc, D Bression, J Racadot and F Peillon 203

Evaluation of hyperprolactinaemia in GH secreting pituitary adenoma: Endocrinological and histological studies
K Kawashima, T Uozumi, K Sakoda and K Mukada 205

Glycoprotein hormone α-subunit secretion by human pituitary adenomas in patients with acromegaly
B Loras, J Trouillas, H Li, A Durand, C Girod and J Betrrand 207

The pituitary-thyroid axis in acromegaly
PC Eskildsen, A Kruse and C Kirkegaard 209

Effect of Sandostatin on hormonal homeostasis: Studies in normal subjects
E del Pozo, HJ Ledermann, M Gonon and C Sieber 213

Somatostatin octapeptide analogue (octreotide) in the medical management of acromegaly
GM Besser and JAH Wass 221

The treatment of acromegaly with SMS 201-995
A Beckers, A Stevenaert, K Kovacs, E Horvath, E Bastings and G Hennen 227

Treatment of acromegaly with the somatostatin analogue SMS 201-995
RA Donald, RC Cueno, JH Livesey, EA Espiner and PD Gluckman 229

Dose and frequency of SMS 201-995 administration on therapeutic efficacy in acromegaly
KY Ho, AJ Weissberger, S Kelland, MC Stuart and L Lazarus 231

High dose, longterm, continuous subcutaneous infusion of SMS 201-995 (Sandostatin) in acromegaly
N Møller, MC White, S Chatterjee, K Hall and P Kendall-Taylor 233

Long-term treatment of acromegaly by continuous subcutaneous infusion of the long acting somatostatin analogue Octreotide (Sandostatin)
JP Tauber, TH Babin, MCR Ducasse, MT Tauber, AG Harris and F Bayard 235

1,25-Dihydroxivitamin D and calcium homeostasis changes in acromegalin patients treated with SMS 201-995
G Pagani, D Gianola, MD Pagani, M Salmoiraghi, G Ghilardi, L Cortesi, S Adami, V Braga and M Montini 241

Long-term surgical results in acromegaly. Does the immediate postoperative growth hormone level predict the outcome?
DK Lüdecke 243

Cure of acromegaly by selective adenomectomy is indicated by normalization of somatomedin-C levels
M Losa, J Schopohl, OA Müller, R Oeckler and K von Werder 253

Slow decrease of IGF-I after adenomectomy in acromegaly
M Arosio, N Bazzani, D Bochicchio, A Aragona and G Faglia 257

Somatomedin-C after transsphenoidal surgery for acromegaly: Endocrinological follow-up study in 67 patients
T Fukushima and M Takami 261

Transphenoidal surgery for acromegaly: Follow-up results
N Arita, S Mori, Y Saitoh, M Nagatani, Y Ushio, T Hayakawa and H Mogami 265

Follow-up study of acromegaly treated by transsphenoidal surgery
K Mukada, T Uozumi, K Sakoda, K Kawashima, M Yamanaka, K Arita and T Yano 267

Prolonged lowering growth hormone effect of radiotherapy in acromegalic patients followed for over 15 years
E Ciccarelli, SM Corsello, AN Harnett, PN Plowman, GM Besser and JAH Wass 269

Radiation cured acromegalics show evidence of a subnormal GH (growth hormone) response to GHRH (GH-releasing hormone)
D Carvalho, M Portocarrero, D Pignatelli, E Vieira and MP Hargreaves 273

Section 6: Prolactinomas

Neuroendocrine regulation of prolactin secretion
S Reichlin 277

Molecular basis for the action of dopaminergic substances
M Cronin, J Anderson, EL Hewlett and JR Zysk 293

Prolactinomas in juveniles
A Pertzelan, B Bauman, R Gurewitz, S Matz, A Silbergeld and Z Laron 303

Hyperprolactinemia and prolactinoma in the treatment of male-to-female transsexuals
H Ascheman, JPH Smits, LJG Gooren and J Assies 309

Treatment of macroprolactinomas with a long-acting, parenteral and repeatable form of bromocriptine
MD Bronstein, NR Musolino, CS Cardim, M Monteiro and R Marino 313

Prolactinoma treatment with long acting bromocriptine
Y Kato, Y Murakami, H Koshiyma, N Hattori and H Imura 317

Impaired regulation of prolactin in patients with persisting normoprolactinemia after withdrawal of long-term therapy with dopamine agonists
W Winkelmann, B Allolio, D Heesen, C Jaursch-Hancke, D Kaulen and M Reincke 321

Effect of pergolide therapy on xenotransplanted human prolactinoma tissue
P-M Schumm-Draeger, E Jungmann, I Steudel, W Saeger and K Schöffling 325

Impaired thyrotropin and gonadotropin secretion in prolactinoma: Pre- and postoperative study
E Ferrari, M Dalzano, S Foppa, PA Bossolo, S Comis, M Zanoletti, C Grugnetti and P Magni 327

Long-term follow-up of patients with "cured" prolactinoma after adenomectomy
E Ciccarelli, E Ghigo, L Savino, M Miola, A Bertagna and F Camanni 331

Clinical, scanographic and hormonal patterns in six bromocriptine resistant prolactinomas
JM Kuhn, A Lavoinne, H Courtois, M Tadié, A Legrand, JY Roussel and LM Wolf 333

Effects of γ-amino-β-hydroxy butyric acid (GABOB) on growth hormone (GH) release in patients with prolactinoma
D Tepavcevic, V Mikulicic, T Jelic, Z Giljevic, B Kopjar, E Suchanek, B Kozic, M Korsic and V Plavsic 335

Paraplegia due to bone and epidural metastases of a prolactinoma
A Visot, F Peillon, M Kujas, J Racadot, M Tremoulet and P Derome 337

Section 7: Cushing's disease

Evidence for hypothalamic or pituitary origin of Cushing's disease. ACTH-cell hyperplasia
SWJ Lamberts and SZ Stefanko 341

A reversible defect in the opiodergic control of ACTH release in Cushings's disease
B Allolio, W Winklemann, D Kaulen, M Reincke, C Jaursch-Hanke, U Schrell and R Fallbusch 349

Results of ACTH and β-LPH determinations in the blood of the inferior petrosal sinus
J Girard, AM Landolt, A Valavanis, AN Eberle and A Pampalone 353

Bilateral inferior petrosal sinus sampling in Cushing's syndrome
EH Oldfield, GP Chrousos, L Neiman, GB Cutler, DL Loriaux and JL Doppman 361

CRF stimulates prolactin secretion from ACTH-producing microadenomas in Cushing's disease: Hormone measurements during catheterization of the inferior petrosal sinus
HM Schulte, B Allolio, RW Günther, G Benker, W Winkelmann, D Reinwein and EE Ohnhaus 363

Correlations between histological and clinical data in 58 cases of Cushing's disease
L Olivier, E Vila-Porcile, J Racadot, P Derome, X Bertagna and JP Luton 367

Failure of oCRH stimulation test in predicting different forms of pituitary-dependent Cushing's disease
A Rampazzo, P Roseano, M Boscaro, M Scanarini and F Mantero 369

Sex steroid receptors in pituitary adenoma of Cushing's disease and Nelson's syndrome - A cytochemical study
M Kurisaka, K Mori, Y Takei and GT Tindall 371

Normal overnight dexamethasone suppression test (ODST) in patients with proven Cushing's disease
LR Sheeler and JW Bay 373

Short and long term surgical results after transsphenoidal surgery for Cushing's disease: Incidence of recurrences
P Derome, O Delalande, A Visot, CP Jedynak and M Dupuy 375

Cure and recurrences after transsphenoidal microsurgery for Cushings's disease
B Ambrosi, P Colombo, SM Gaini, M Giovanelli and G Faglia 381

Evaluation of the efficacy of a treatment regimen for ACTH-secreting pituitary adenomas associated with Nelson's syndrome
M Buchfelder, R Fahlbusch, U Schrell, GK Stalla and OA Müller 383

Section 8: Glycoprotein hormone secreting and endocrine inactive adenomas

Glycoprotein gene expression and hormone production in pituitary adenomas
JL Jameson, A Klibanski, PMcL Black, D Hsu, CM Lindell, NT Zervas and EC Ridgway 387

α-Subunit in pituitary adenomas: a radioimmunoassay and immunohistochemical study
KK Berg, BW Scheithauer, GG Klee, ER Laws, K Kovacs, E Horvath and BS Preissner 397

Hormone products of apparently non-functioning pituitary adenomas
PMcL Black, L Jameson, DW Hsu, A Klibanski, ET Hedley-Whyte, EC Ridgway, JF Habener and NT Zervas 413

"Non functioning adenomas" in vivo and in vitro
D J Kwekkeboom, M Leunisse, L van der Zwan, FH de Jong and SWJ Lamberts 417

Serum thyrotropin (TSH) bioactivity in patients with TSH-secreting pituitary tumors
M Nissim, PA Dahlberg, P Beck-Peccoz, PR Petrick, J Bevan, G Faglia and BD Weintraub 421

Thyrotropic pituitary adenomas. Secretion of heterogenous forms of immunoreactive thyroid stimulating hormone
R Buonaguidi, F Faggionato, M Ferdeghini and J Trouillas 425

Effect of SMS 201-995 in the treatment of neoplastic TSH secretion syndrome
M Montini, MD Pagani, D Gianola, M Salmoiraghi, G Ghilardi, D Parodi, M Piolini, GP Tonnarelli and G Pagani 429

Postoperative evaluation of adrenocortical function by a corticotropin-releasing factor (CRF) test in patients with large pituitary adenomas
E Jungmann, P Reiner, E Luderer, C Rosak, P-H Althoff and K Schöffling 431

Gonadotropic adenoma with abnormal secretory pattern: Case report adenoma
M Duet, A Warnet, D Roche, D Seret, SN Diop and J Lubetzki 433

Mixed LH, FSH, GH pituitary microadenoma: Clinical and morphological studies
P Travaglini, M Bassetti, A Spada, ME Togni and G Faglia 435

The significance of α-subunit in gonadotropin-producing pituitary adenomas
R Demura, O Kubo, K Jibiki, E Odagiri, H Demura, K Shizume and K Kitamura 437

Oncocytomas of the pituitary gland: A clinicopathological study
JW Bay, L Sheeler and M Estes 439

Section 9: Pituitary surgery

Intraoperative radio frequency enhancement of pituitary microadenomectomy
NT Zervas and J Pillips 443

The use of the neodynium-YAG-laser in pituirary surgery: Clinical results and indications
R Oeckler, K von Werder and OA Müller 447

Radiosurgery in pituitary adenomas
T Rähn and M Thorén 451

Section 10: Vascular and immune disorders

Changes in perfusion characteristics and blood flow in pituitary tumours
PD Lees, H Richards and JD Pickard 457

Non-haemorrhagic infarction of pituitary tumours presenting as pituitary apoplexy
JC de Villiers and G Marus 461

Lymphocytic hypophysitis -- autoimmune reaction?
AD Parent, JM Cruse, EE Smith and RR Smith 465

Subject index 471